Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | 225Ac-FPI-1434 |
Synonyms | |
Therapy Description |
225Ac-FPI-1434 is a radioconjugate comprising a monoclonal antibody that targets IGF-1R linked to the radionuclide Actinium-225, which delivers radiation to tumor cells and potentially inhibits tumor growth (Journal of Medical Imaging and Radiation Sciences 50, no. 4 (2019): S86; J Clin Oncol 2019 37:15_suppl, TPS3152). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
225Ac-FPI-1434 | [225Ac]-FPI-1434|[Ac-225]-FPI-143|FPX 01|FPX-01|FPX01 | 225Ac-FPI-1434 is a radioconjugate comprising a monoclonal antibody that targets IGF-1R linked to the radionuclide Actinium-225, which delivers radiation to tumor cells and potentially inhibits tumor growth (Journal of Medical Imaging and Radiation Sciences 50, no. 4 (2019): S86; J Clin Oncol 2019 37:15_suppl, TPS3152). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03746431 | Phase Ib/II | 225Ac-FPI-1434 | A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | Recruiting | USA | CAN | AUS | 0 |